Clinical trials: Hepatitis C Recurrent
Liver Transplantation
Gene Expression in Liver Allograft Rejection and Recurrent Hepatitis C
Acute cellular rejection is relatively common after liver transplantation, typically does not affect graft survival, and is not associated with the development of chronic rejection.
- Trial name
- NCT01428700
- Volunteers
- 275 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis C
Ribavirin Pre-treatment Followed by Combined Standard Therapy in Hepatitis C Virus (HCV) Recipients
The results of antiviral therapy in patients with recurrent hepatitis C after liver transplantation are lower than standard. Ribavirin has immune-modulating effects and seems to be crucial to optimize viral treatment.
- Trial name
- RBV (NCT00993122)
- Testing
- ribavirin pre-treatment
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- University of Roma La Sapienza